{"id":"https://openalex.org/W3136100433","doi":"https://doi.org/10.2147/ott.s301500","title":"Anti\u2013PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status","display_name":"Anti\u2013PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status","publication_year":2021,"publication_date":"2021-03-01","ids":{"openalex":"https://openalex.org/W3136100433","doi":"https://doi.org/10.2147/ott.s301500","mag":"3136100433","pmid":"https://pubmed.ncbi.nlm.nih.gov/33762828","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7982715"},"language":"en","primary_location":{"id":"doi:10.2147/ott.s301500","doi":"https://doi.org/10.2147/ott.s301500","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s301500","pdf_url":"https://www.dovepress.com/getfile.php?fileID=67723","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=67723","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5106721514","display_name":"Taichi Matsubara","orcid":"https://orcid.org/0000-0002-3976-7722","observed_orcids":["https://orcid.org/0000-0002-3976-7722"]},"institutions":[{"id":"https://openalex.org/I4210093709","display_name":"National Hospital Organization Kyushu Cancer Center","ror":"https://ror.org/00mce9b34","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210093709","https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Taichi Matsubara","raw_affiliation_strings":["Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan","institution_ids":["https://openalex.org/I4210093709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067259938","display_name":"Takashi Seto","orcid":"https://orcid.org/0000-0002-2960-4364","observed_orcids":["https://orcid.org/0000-0002-2960-4364"]},"institutions":[{"id":"https://openalex.org/I4210093709","display_name":"National Hospital Organization Kyushu Cancer Center","ror":"https://ror.org/00mce9b34","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210093709","https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Takashi Seto","raw_affiliation_strings":["Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan","institution_ids":["https://openalex.org/I4210093709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069784331","display_name":"Shinkichi Takamori","orcid":"https://orcid.org/0000-0001-8175-6798","observed_orcids":["https://orcid.org/0000-0001-8175-6798"]},"institutions":[{"id":"https://openalex.org/I4210093709","display_name":"National Hospital Organization Kyushu Cancer Center","ror":"https://ror.org/00mce9b34","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210093709","https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Shinkichi Takamori","raw_affiliation_strings":["Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan","institution_ids":["https://openalex.org/I4210093709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089707512","display_name":"Takatoshi Fujishita","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093709","display_name":"National Hospital Organization Kyushu Cancer Center","ror":"https://ror.org/00mce9b34","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210093709","https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Takatoshi Fujishita","raw_affiliation_strings":["Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan","institution_ids":["https://openalex.org/I4210093709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001895894","display_name":"Ryo Toyozawa","orcid":"https://orcid.org/0009-0002-7688-5725","observed_orcids":["https://orcid.org/0009-0002-7688-5725"]},"institutions":[{"id":"https://openalex.org/I4210093709","display_name":"National Hospital Organization Kyushu Cancer Center","ror":"https://ror.org/00mce9b34","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210093709","https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Ryo Toyozawa","raw_affiliation_strings":["Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan","institution_ids":["https://openalex.org/I4210093709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102482353","display_name":"Kensaku Ito","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093709","display_name":"National Hospital Organization Kyushu Cancer Center","ror":"https://ror.org/00mce9b34","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210093709","https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Kensaku Ito","raw_affiliation_strings":["Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan","institution_ids":["https://openalex.org/I4210093709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009383534","display_name":"Masafumi Yamaguchi","orcid":"https://orcid.org/0000-0002-5601-4749","observed_orcids":["https://orcid.org/0000-0002-5601-4749"]},"institutions":[{"id":"https://openalex.org/I4210093709","display_name":"National Hospital Organization Kyushu Cancer Center","ror":"https://ror.org/00mce9b34","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210093709","https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Masafumi Yamaguchi","raw_affiliation_strings":["Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"],"raw_orcid":"https://orcid.org/0000-0002-5601-4749","affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan","institution_ids":["https://openalex.org/I4210093709"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006205474","display_name":"Tatsuro Okamoto","orcid":"https://orcid.org/0000-0002-3568-1876","observed_orcids":["https://orcid.org/0000-0002-3568-1876"]},"institutions":[{"id":"https://openalex.org/I4210093709","display_name":"National Hospital Organization Kyushu Cancer Center","ror":"https://ror.org/00mce9b34","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210093709","https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Tatsuro Okamoto","raw_affiliation_strings":["Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan","institution_ids":["https://openalex.org/I4210093709"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5001895894","https://openalex.org/A5006205474","https://openalex.org/A5009383534","https://openalex.org/A5067259938","https://openalex.org/A5069784331","https://openalex.org/A5089707512","https://openalex.org/A5102482353","https://openalex.org/A5106721514"],"corresponding_institution_ids":["https://openalex.org/I4210093709"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":1.3005,"has_fulltext":true,"cited_by_count":14,"citation_normalized_percentile":{"value":0.82617252,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"Volume 14","issue":null,"first_page":"1961","last_page":"1968"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.875},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9010000228881836},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.7170000076293945},{"id":"https://openalex.org/keywords/poor-performance-status","display_name":"poor performance status","score":0.9879999756813049},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.9470000267028809},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9509999752044678},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.824999988079071},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9750000238418579},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.6499999761581421}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.923902153968811},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.789452075958252},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.7390339374542236},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7202145457267761},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6140581965446472},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6058017611503601},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.5127611756324768},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.47352930903434753},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3752829134464264},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36823439598083496},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.22956979274749756}],"mesh":[],"locations_count":5,"locations":[{"id":"doi:10.2147/ott.s301500","doi":"https://doi.org/10.2147/ott.s301500","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s301500","pdf_url":"https://www.dovepress.com/getfile.php?fileID=67723","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7982715","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7982715","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Onco Targets Ther","raw_type":"Text"},{"id":"pmid:33762828","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33762828","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:5247b9248d744857bce6b1aa05ca5641","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/5247b9248d744857bce6b1aa05ca5641","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"OncoTargets and Therapy, Vol Volume 14, Pp 1961-1968 (2021)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/63152","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/antindashpd-1-monotherapy-for-advanced-nsclc-patients-with-older-age-o-peer-reviewed-article-OTT","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.2147/ott.s301500","doi":"https://doi.org/10.2147/ott.s301500","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s301500","pdf_url":"https://www.dovepress.com/getfile.php?fileID=67723","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G225541505","display_name":"Investigation of the Effect of Myokine on Immunotherapeutic Efficacy and Safety in Patients with Non-Small Cell Lung Cancer","funder_award_id":"20K16432","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"}],"funders":[{"id":"https://openalex.org/F4320334764","display_name":"Japan Society for the Promotion of Science","ror":"https://ror.org/00hhkn466"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3136100433.pdf","grobid_xml":"https://content.openalex.org/works/W3136100433.grobid-xml"},"referenced_works_count":27,"referenced_works":["https://openalex.org/W2156353875","https://openalex.org/W2260064945","https://openalex.org/W2288908606","https://openalex.org/W2373606074","https://openalex.org/W2435563082","https://openalex.org/W2527905628","https://openalex.org/W2559382297","https://openalex.org/W2567564314","https://openalex.org/W2572174216","https://openalex.org/W2613260339","https://openalex.org/W2770828094","https://openalex.org/W2776730914","https://openalex.org/W2796929908","https://openalex.org/W2889646458","https://openalex.org/W2901692833","https://openalex.org/W2910245285","https://openalex.org/W2943701399","https://openalex.org/W2947825353","https://openalex.org/W2962053530","https://openalex.org/W2979129241","https://openalex.org/W3000469764","https://openalex.org/W3009082159","https://openalex.org/W3023823544","https://openalex.org/W3089120188","https://openalex.org/W3089123861","https://openalex.org/W3095154565","https://openalex.org/W3113497263"],"related_works":["https://openalex.org/W2895908834","https://openalex.org/W3024361908","https://openalex.org/W2790782691","https://openalex.org/W4210625632","https://openalex.org/W2982171580","https://openalex.org/W2776730914","https://openalex.org/W6902166931","https://openalex.org/W4396722240","https://openalex.org/W2981333377","https://openalex.org/W7111464096"],"abstract_inverted_index":{"PURPOSE:":[0],"Anti-programmed":[1],"death":[2,173],"1":[3,175],"(PD-1)":[4],"antibodies":[5],"have":[6],"emerged":[7],"as":[8,114,191,193],"frontline":[9],"treatments":[10],"for":[11,258],"patients":[12,38,68,86,103,135,194,217,238,247,259],"with":[13,39,43,70,109,143,168,184,195,218,239,248,260],"advanced":[14],"non-small":[15],"cell":[16],"lung":[17],"cancer":[18],"(NSCLC)":[19],"on":[20],"the":[21,53,188,205,225],"basis":[22],"of":[23,56,92,207],"global":[24],"Phase":[25],"III":[26],"trials.":[27],"However,":[28,162,251],"current":[29],"data":[30],"regarding":[31],"responses":[32],"to":[33,79],"anti-PD-1":[34,71],"therapy":[35,230],"in":[36,60,133,141,178,187,204,234,246],"older":[37,102,134,158,222,235],"NSCLC":[40],"or":[41,74,221],"those":[42,108,142],"poor":[44,116,144,163,169,196,219,249,261],"performance":[45],"status":[46],"(PS)":[47],"are":[48],"limited.":[49],"Therefore,":[50],"we":[51],"examined":[52,66],"therapeutic":[54],"effect":[55],"anti":[57],"PD-1":[58],"antibody":[59],"these":[61],"patients.":[62,161,227],"PATIENTS:":[63],"We":[64,83],"retrospectively":[65],"consecutive":[67],"treated":[69],"monotherapy":[72],"(pembrolizumab":[73],"nivolumab)":[75],"from":[76],"January":[77],"2016":[78],"September":[80],"2018.":[81],"RESULTS:":[82],"enrolled":[84],"125":[85],"(median":[87],"age,":[88],"60":[89],"years),":[90],"80.8%":[91],"whom":[93],"were":[94,100,112,128],"men.":[95],"Patients":[96],"aged":[97],"\u226575":[98],"years":[99],"considered":[101,257],"(n":[104,118],"=":[105,119],"15),":[106],"and":[107,124,130,136,138,149,159,224,236],"PS":[110,117,164,220,262],"2-3":[111],"regarded":[113],"having":[115],"11).":[120],"The":[121],"objective":[122],"response":[123],"disease":[125],"control":[126],"rates":[127],"15.4%":[129],"46.2%,":[131],"respectively,":[132,140],"9.1%":[137],"27.3%,":[139],"PS.":[145,197,250],"Progression-free":[146],"survival":[147,151,186,242],"(PFS)":[148],"overall":[150],"(OS)":[152],"did":[153],"not":[154],"significantly":[155,166,244],"differ":[156],"between":[157,216],"younger":[160,237],"was":[165,182,243],"associated":[167,183],"survival.":[170],"High":[171],"programmed":[172],"ligand":[174],"(PD-L1)":[176],"expression":[177],"tumor":[179],"specimens":[180],"(\u226550%)":[181],"favorable":[185],"entire":[189],"cohort":[190],"well":[192],"Safety":[198],"analyses":[199],"demonstrated":[200],"no":[201],"significant":[202],"difference":[203],"occurrence":[206],"any":[208],"adverse":[209,214],"event,":[210],"including":[211],"grade":[212],"\u22653":[213],"events,":[215],"age":[223],"remaining":[226],"CONCLUSION:":[228],"Anti-PD-1":[229],"had":[231],"similar":[232],"efficacy":[233],"NSCLC,":[240],"whereas":[241],"worse":[245],"immune":[252],"checkpoint":[253],"inhibitors":[254],"may":[255],"be":[256],"harboring":[263],"positive":[264],"PD-L1":[265],"expression.":[266]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-03-29T00:00:00"}